Can dermatomyositis cause death?

Can dermatomyositis cause death?

Conclusions. Dermatomyositis and polymyositis are serious diseases with a disease‐related mortality of at least 10%.

Can you have dermatomyositis with a negative myositis panel?

It has also been seen that patients who test negative to routine myositis antibody panels have a higher risk for malignancy. The combination of these two approaches is 94% sensitive, with 100% sensitivity and negative predictive value in dermatomyositis.

What is Jo-1 polymyositis?

Anti–Jo-1 antibodies are almost completely specific for myositis and are more common in polymyositis than in dermatomyositis; they are rare in children. The presence of anti-Jo-1 antibodies defines a distinct group of polymyositis patients with interstitial lung disease, arthritis, and fevers.

What is life expectancy with dermatomyositis?

The life loss of male patients with dermatomyositis complicated with malignant tumors was 30.1 years, and that of females was 38.6 years; the life loss of male patients with polymyositis was 27.6 years, and that of females was 22.1 years.

What are the clinical characteristics of patients with anti Jo-1 antibodies?

Clinical Characteristics of Patients With Anti-Jo-1 Antibodies. Of these patients, 2 had anti Jo-1 antibodies. In patients with the antisynthetase syndrome, the lung involvement usually determines the prognosis of the disease. 3 In another series, 3 patients with Jo-1 antibodies developed fatal acute respiratory distress syndrome.

Which antibodies are associated with cancer-associated dermatomyositis?

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum2013;65:2954-62. 10.1002/art.38093 [PMC free article][PubMed] [CrossRef] [Google Scholar]

Can anti-Jo-1 antibodies predict interstitial lung disease in patients with polymyositis?

Anti-Jo-1 antibody in patients with polymyositis/dermatomyositis Interstitial lung disease (ILD) has been recognized as a manifestation of polymyositis or dermatomyositis (PM/DM). Patients with PM/DM with anti-Jo-1 antibody had a higher incidence of ILD. Thirty-five patients with PM/DM were studied the antibodies.

Do anti-Jo-1 autoantibodies influence the phenotype of patients with idiopathic inflammatory myopathies?

Such an association between arthralgia or arthritis and anti-Jo-1 positivity has also been observed among patients with multiple types of idiopathic inflammatory myopathies [ 9, 12, 14 ]. Thus, a marked influence of anti-Jo-1 autoantibodies on the phenotype of patients with DM and joint involvement can be inferred.

Related Post